Soumit Roy analyst JONESTRADING

Currently out of the existing stock ratings of Soumit Roy, 18 are a BUY (72%), 7 are a HOLD (28%).

Soumit Roy

Work Performance Price Targets & Ratings Chart

Analyst Soumit Roy, currently employed at JONESTRADING, carries an average stock price target met ratio of 21.67% that have a potential upside of 36.9% achieved within 59 days.

Soumit Roy’s has documented 43 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DCPH, Deciphera Pharmaceuticals LLC at 29-Apr-2024.

Wall Street Analyst Soumit Roy

Analyst best performing recommendations are on AVEO (AVEO PHARMACEUTICALS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 4/11/2024. The price target of $10 was fulfilled within 196 days with a profit of $6.15 (159.74%) receiving and performance score of 8.15.

Average potential price target upside

DCPH Deciphera Pharmaceuticals LLC INFI Infinity Pharmaceuticals AVEO AVEO Pharmaceuticals SAVA Cassava Sciences SBTX Silverback Therapeutics  IKT Inhibikase Therapeutics  RAIN Rain Therapeutics TCON TRACON Pharmaceuticals MRTX Mirati Ther MNPR Monopar Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$26

$0.41 (1.60%)

$9

7 months 21 days ago
(30-Apr-2024)

3/10 (30%)

$0.73 (2.89%)

235

Buy

$23

7 months 21 days ago
(30-Apr-2024)

4/6 (66.67%)

$8.58 (59.50%)

353

Buy

$22

7 months 21 days ago
(30-Apr-2024)

2/3 (66.67%)

$2.24 (11.34%)

67

Buy

$25.6

$0.01 (0.04%)

7 months 22 days ago
(29-Apr-2024)

0/3 (0%)

$10.95 (74.74%)

Hold

$14

$-11.59 (-45.29%)

$52

1 years 1 months 1 days ago
(20-Nov-2023)

4/4 (100%)

$1.66 (13.45%)

92

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Soumit Roy?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?